Literature DB >> 1496162

Salivary and oral components of Sjögren's syndrome.

T E Daniels1, P C Fox.   

Abstract

The intraoral symptoms and signs of SS are not specific to SS, being shared with other conditions in which salivary function is diminished. The decrease in saliva causes chronic oral discomfort and functional problems and predisposes patients to dental caries and oral candidiasis. Many methods have been used to assess SGs in SS objectively, but at present a labial salivary gland biopsy specimen showing focal lymphocytic sialadenitis provides the best diagnostic criterion for the salivary component of SS, in terms of its disease specificity, convenience, availability, and low risk. The treatment of xerostomia in patients with SS consists of (1) preventing new and recurrent dental caries by frequent and regular application of topical fluoride, careful dental supervision, and avoidance of sucrose and other metabolizable carbohydrates between meals; (2) reducing oral symptoms by diagnosing and treating oral candidiasis (repeatedly if necessary); and (3) attempting to replace lost saliva by stimulating salivary secretion with physiologic sialogogues or pilocarpine, or if adequate amounts of saliva cannot be stimulated, using some form of saliva substitute, especially for patients wearing complete dentures.

Entities:  

Mesh:

Year:  1992        PMID: 1496162

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  35 in total

1.  Distinct contributions by ionotropic purinoceptor subtypes to ATP-evoked calcium signals in mouse parotid acinar cells.

Authors:  Sumit Bhattacharya; Douglas S Verrill; Kristopher M Carbone; Stefanie Brown; David I Yule; David R Giovannucci
Journal:  J Physiol       Date:  2012-03-25       Impact factor: 5.182

2.  Clock genes show circadian rhythms in salivary glands.

Authors:  L Zheng; Y J Seon; J McHugh; S Papagerakis; P Papagerakis
Journal:  J Dent Res       Date:  2012-06-14       Impact factor: 6.116

3.  Endothelial dysfunction in patients with primary Sjögren's syndrome.

Authors:  Timur Pirildar; Canan Tikiz; Sabriye Ozkaya; Serdar Tarhan; Ozan Utük; Hakan Tikiz; Uğur Kemal Tezcan
Journal:  Rheumatol Int       Date:  2005-06-17       Impact factor: 2.631

4.  ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands.

Authors:  Joel W Nelson; Noel J Leigh; Rachel E Mellas; Andrew D McCall; Alfredo Aguirre; Olga J Baker
Journal:  Am J Physiol Cell Physiol       Date:  2013-11-20       Impact factor: 4.249

5.  Male NOD mouse external lacrimal glands exhibit profound changes in the exocytotic pathway early in postnatal development.

Authors:  Silvia R da Costa; Kaijin Wu; Michelle Mac Veigh; Mike Pidgeon; Chuanqing Ding; Joel E Schechter; Sarah F Hamm-Alvarez
Journal:  Exp Eye Res       Date:  2005-07-11       Impact factor: 3.467

Review 6.  Ca²⁺-dependent K⁺ channels in exocrine salivary glands.

Authors:  Marcelo A Catalán; Gaspar Peña-Munzenmayer; James E Melvin
Journal:  Cell Calcium       Date:  2014-01-31       Impact factor: 6.817

Review 7.  Cytokines in Sjögren's syndrome.

Authors:  N Roescher; P P Tak; G G Illei
Journal:  Oral Dis       Date:  2009-06-10       Impact factor: 3.511

8.  MALT lymphoma in labial salivary gland biopsy from Sjögren syndrome: importance of follow-up in early detection.

Authors:  A Keszler; L I Adler; M S Gandolfo; P A Masquijo Bisio; A C Smith; C F Vollenweider; A M Heidenreich; G de Stefano; M V Kambo; D P Cox; M Narbaitz; H E Lanfranchi
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-11-13

9.  [Recurrent abcesses of the parotid gland in Sjögren's syndrome].

Authors:  A Knopf; A Pickhard; T Stark; S Schulz; E Q Scherer
Journal:  HNO       Date:  2009-09       Impact factor: 1.284

10.  Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States.

Authors:  Barbara Segal; Simon J Bowman; Philip C Fox; Frederick B Vivino; Nandita Murukutla; Jeff Brodscholl; Sarika Ogale; Lachy McLean
Journal:  Health Qual Life Outcomes       Date:  2009-05-27       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.